Medication info
Linacan Empa Tablet 25/5 mg (Empagliflozin, Linagliptin)

Linacan Empa Tablet 25/5 mg (Empagliflozin, Linagliptin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›5mg / 1 tabletEmpagliflozin Amorphous›25mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated double tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202501803 · Approved 2025.07.15 · Insurance code 653406090

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If empagliflozin 10 mg/linagliptin 5 mg is tolerated but additional glycemic control is needed, the dose may be increased to 25/5 mg once daily. Patients switching to this medicine from combination therapy with empagliflozin and linagliptin should receive their previous doses. This medicine may be taken with or without food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. However, if the next dose is due within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This medicine is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. Elderly patients No dose adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is used as an adjunct therapy together with dietary and exercise therapy to assist in blood sugar control in patients with type 2 diabetes, where empagliflozin and linagliptin work together to effectively manage blood sugar.

How to take

Adult dose

The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If empagliflozin 10 mg/linagliptin 5 mg is tolerated but additional glycemic control is needed, the dose may be increased to 25/5 mg once daily. Patients switching to this medicine from combination therapy with empagliflozin and linagliptin should receive their previous doses. This medicine may be taken with or without food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. However, if the next dose is due within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This medicine is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. Elderly patients No dose adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This drug consists of two components, empagliflozin and linagliptin, and is mainly used for the treatment of type 2 diabetes. This drug should not be used in certain patients, including those who are hypersensitive to empagliflozin, linagliptin, or any of the components of the drug, patients with type 1 diabetes, patients with diabetic ketoacidosis, or those on dialysis. During use, renal function should be periodically monitored, especially in patients with decreased renal function or those taking other medications that may affect renal function. Patients with heart failure or a history of acute pancreatitis should also be cautious when using this drug, and if symptoms of pancreatitis, such as persistent severe abdominal pain, occur, the medication should be stopped immediately and a doctor consulted. Additionally, a rare skin blistering condition may develop, so any skin blisters or abrasions should be reported to a doctor immediately. The most common side effect during the use of this drug is a urinary tract infection; other possible side effects include hypoglycemia, thirst, cough, constipation, itching, and rash. Caution is especially warranted in cases where insulin or sulfonylurea is used concurrently, as the risk of hypoglycemia may increase. This medication can cause a serious metabolic disorder called ketoacidosis; if symptoms such as vomiting, abdominal pain, or difficulty breathing occur, immediate treatment is necessary. Additionally, reduction in fluid volume can lead to low blood pressure or dehydration, so elderly patients or those with low blood pressure should be particularly careful. There is also an increased risk of genital infections, so if related symptoms occur, appropriate treatment should be sought. Women who are pregnant or breastfeeding are advised not to use this medication, and it is not recommended for children under 18 years of age, as safety and efficacy have not been established. In case of overdose, seek medical attention immediately for appropriate treatment, and this medication should be kept out of the reach of children. Finally, while taking this medication, caution should be exercised while driving or operating machinery due to the risk of accidents from hypoglycemia.

Side effects

Urinary tract infection, vulvovaginitis, vulvitis, balanitis, genital infections, hypersensitivity, angioedema, urticaria, hypoglycemia, thirst, ketosis, cough, constipation, pancreatitis, oral ulcer formation, itching, rash, vesicular pemphigoid, rhabdomyolysis, blood volume depletion, increased urination, difficulty urinating, interstitial nephritis, amylase increase, lipase increase, increased hematocrit, increased serum lipids, increased blood creatinine, decreased glomerular filtration rate, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech impairment, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, cerebral infarction, headache, drowsiness, chest discomfort, weakness, nosebleed, oropharyngeal pain, voice disorder, allergic rhinitis, exercise-induced dyspnea, productive cough, asthma, runny nose, lung mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased blood triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased blood creatinine, increased blood creatine phosphokinase activity, ALT increase, increased blood triglycerides, androgenetic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, meniscal injury, foot fracture, hand fracture, pneumoconiosis, palpitations, tachycardia, atherosclerosis, deep vein thrombosis, diabetic vascular complications, peripheral artery occlusive disease, thyroid goiter, anemia, lymphadenopathy, vulvovaginal pruritus, genital pruritus, dyslipidemia, obesity, hyponatremia, dermoid cyst, seborrheic dermatitis, atopic dermatitis, nummular eczema, heat rash, sebaceous gland hyperplasia, lumbar spinal canal stenosis, myalgia, limb pain, musculoskeletal chest pain, cervical stenosis, fibromyalgia, flank pain, fracture pain, muscular weakness, osteoarthritis, astigmatism, allergic conjunctivitis, blurred vision, corneal erosion, macular fibrosis, eye discomfort, ocular congestion, visual impairment, vitreous floaters, vitreous hemorrhage, epistaxis, exertional dyspnea, wet cough, residual sputum, epistaxis, otalgia, positional vertigo, vertigo, hypothyroidism, thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated double tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.